Pfizer Inc PFE

$30.79 +0.79 (2.63%)

Valuation

Market cap
170,990,224,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
10.06
P/E (forward)
10.42
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
49,921,000
Avg volume
32,914,395
Day's range
$30.04 – $30.90
Shares out
5,699,674,000
Stochastic %K
85%
Beta
0.31
Analysts
Hold
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

GTA_Terminal Nov 5, 5:40 AM
Unusual options activity in $PFE, mostly calls. Calls on top of a one-month high. Either late to the party or early to the next leg. Which is it? Several of the big contracts traded above open interest, which points to new positions, not traders closing old ones. Look up any stock's options flow and dark pools on the GTA Terminal, free for 14 days: https://globaltradersacademy.com/?utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PFE Read the full article for the full details: https://globaltradersacademy.com/articles/pfizer-pfe-institutional-flow-at-the-close-wednesday-nov-4-75-of-the-options?utm_source=stocktwits&utm_medium=social
0 replies
Jefftennis36 Nov 5, 1:29 AM
$PFE going to squeeze at least into ex Div
0 replies
Mountainmannn Nov 5, 1:06 AM
$ABUS it's actually in $MRNA best interest to lose this argument. They don't lose anything more than a billion dollars. And they can buy these companies for $2 to $5 billion dollars in settlement agreement. Then go after $PFE for royalties.. develop the pipeline for even more billions. Buying with stock would be a no brainier they are up hundreds of billion or so? $MRNA ↓
1 replies
Jason_Vollmer Nov 5, 12:35 AM
Ticker SCAG news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG only 1.3 million shares float - Chinese - On watch. $PDD $NET $PFE $RDDT $MARA 💮💮
0 replies
Axos300 Nov 4, 10:54 PM
$PFE I'm still long here. Sitting on about a 10% profit. I worry about that patent cliff.
0 replies
jrh34 Nov 4, 10:19 PM
$AMD and $PFE two must own stocks for 2027. Lots of growth ahead.
1 replies
Jefftennis36 Nov 4, 10:11 PM
$PFE 32 tomorrow to get in before Div ??
0 replies
TheRagnirLothbrok Nov 4, 9:59 PM
Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $RVSN $INTC $PFE wont sell
0 replies